Inhibition of SIK1 Alleviates the Pathologies of Psoriasis by Disrupting IL‐17 Signaling
Mediators of Inflammation · 2025
DOI: 10.1155/mi/3540219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, 2025. Verfasst von Dongxuan Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Psoriasis is an inflammatory skin disease mediated by multiple immune cells, including T cells, macrophages, and dendritic cells, which exhibit complex pathologies and limited clinical treatment. Here, we found that salt‐inducible kinase 1 (SIK1) was upregulated in the imiquimod (IMQ)‐induced psoriasis mouse model. This increment may be due to a higher level of interleukin‐17, which promoted the expression of SIK1 in keratinocytes. Inhibition of SIK1 kinase activity using a small molecular inhibitor (HG‐9‐91‐01 or YKL‐06‐062) dramatically alleviated IMQ‐induced psoriasis, showing reduced epidermal thickness, inflammation, and hyperproliferative epidermal keratinocytes. Our data demonstrated that SIK1 inhibitors HG‐9‐91‐01 or YKL‐06‐062 blocked the expression of IL‐17‐induced proinflammatory cytokines and chemokines, including Il6 , Kc , and Ccl20 . Mechanistically, we found that SIK1 inhibitor HG‐9‐91‐01 or YKL‐06‐062 suppressed the phosphorylation of I κ b α and P38. Consistently, SIK1 overexpression in keratinocytes promoted the activation of I κ b α and P38. Collectively, our results reveal that SIK1 participates to promote IL17‐induced signaling through enhancing activation of NF‐ κ B and MAPKs and exacerbates psoriasis‐like skin inflammation. Thus, inhibition of SIK1 presents a potential new therapeutic target for psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China.
- Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110, China.
- Department of Nephrology, Shenzhen Longhua District Central Hospital, Shenzhen Longhua District Key Laboratory for Diagnosis and Treatment of Chronic Kidney Disease, Shenzhen 518110, China.
- Department of Clinical Laboratory, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518110, China.
ORCID-Profile: Hanchao Gao, Mengtao Cao
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Huang, D., Sun, H., Su, L., Yang, F., Huang, D., Gao, H., & Cao, M. (2025). Inhibition of SIK1 Alleviates the Pathologies of Psoriasis by Disrupting IL‐17 Signaling. Mediators of Inflammation. https://doi.org/10.1155/mi/3540219
Vancouver
Huang D, Sun H, Su L, Yang F, Huang D, Gao H, et al. Inhibition of SIK1 Alleviates the Pathologies of Psoriasis by Disrupting IL‐17 Signaling. Mediators of Inflammation. 2025. doi:10.1155/mi/3540219
BibTeX
@article{Huang2025,
author = {Huang, Dongxuan and Sun, Huimin and Su, Lianhui and Yang, Fan and Huang, Dongsheng and Gao, Hanchao and Cao, Mengtao},
title = {Inhibition of SIK1 Alleviates the Pathologies of Psoriasis by Disrupting IL‐17 Signaling},
journal = {Mediators of Inflammation},
year = {2025},
doi = {10.1155/mi/3540219}
}
EUVIMED